中國生物製藥(01177.HK):TQB3142“Bcl-xL PROTAC”臨牀試驗申請獲NMPA受理
格隆匯8月12日丨中國生物製藥(01177.HK)公佈,集團自主研發的創新藥TQB3142「Bcl-xL PROTAC (蛋白降解靶向嵌合體)」的新藥臨牀試驗申請(IND)已獲得中國國家藥品監督管理局(NMPA)受理,擬用於治療惡性腫瘤。
TQB3142是一款靶向降解Bcl-xL蛋白的PROTAC分子,通過泛素-蛋白酶體系統特異性降解Bcl-xL蛋白,解除其對腫瘤細胞凋亡的抑制,從而激活Caspase級聯反應,誘導腫瘤細胞程序性死亡。研究顯示,TQB3142在多種移植瘤模型中表現出顯著抑瘤活性,且對血小板毒性風險低於同類候選藥物,具有更優的治療窗口,代謝風險可控。
目前,全球尚無Bcl-xL抑制劑獲批上市,TQB3142是一款全新機制的抗腫瘤藥物。TQB3142通過優化分子設計,在保持降解活性的同時,能夠降低血液毒性風險,有望爲惡性腫瘤患者提供新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.